A fixed-dose combination of ledipasvir and sofosbuvir was an effective treatment for HIV patients co-infected with HCV genotype 1 or 4, according to a study published in New England Journal of ...

Vir Biotechnology (NASDAQ:VIR) on Friday announced 24-week post-end-of-treatment data from a mid-stage trial for tobevibart and elebsiran, a combination therapy developed for chronic Hepatitis B ...

A panelist discusses how the new doravirine and islatravir combination offers an alternative to integrase inhibitor-based therapies, particularly useful for patients with integrase inhibitor ...

The analysis included adult patients (N=72,920) with HIV infection who were stratified into groups to determine the prevalence of HCV over 3 calendar periods, including the IFN-based DAA era (2011 ...

The agreement allows manufacturers to develop, manufacture and supply generic long-acting injectable cabotegravir for ...

Title: Efficacy and safety of tobevibart (VIR-3434) alone or in combination with elebsiran (VIR-2218) in participants with chronic hepatitis delta virus infection: preliminary results from the ...

MMF at a dose of 0.5–2 g daily has been effective at inducing a partial response or complete remission in 39–84% of autoimmune hepatitis patients who did not respond to conventional therapy.

He is convinced that, as it happened with antiretroviral therapy, virus cure will also come from a "combination of strategies." "Curing HIV will require at least two conceptual convergences," the ...

In 2021, federal regulators approved the first long-acting antiretroviral (LA-ART) injectable, which is a combination of long-acting cabotegravir and rilpivirine. But they only approved it for HIV ...